Abstract:

IgA nephropathy （IgAN） is one of the most prevalent forms of primary glomerulonephritis globally and a leading cause of end?stage renal disease （ESRD）. The exact pathogenesis and progression mechanisms of IgAN remain unclear. Its clinical manifestations are diverse， with varying degrees of kidney involvement reflected in both clinical presentations and pathological changes. Consequently， responses to treatment and prognoses differ significantly among patients. Currently， renal needle biopsy serves as the gold standard for diagnosing IgAN； however， this invasive procedure is often not well?accepted by patients， limiting its widespread clinical application and complicating disease diagnosis. Therefore， non?invasive biomarkers are crucial for assisting in the diagnosis of IgAN and evaluating the risk of disease progression. Below， we will focus on various serum and urinary biomarkers associated with IgAN at both protein and nucleic acid levels.

Key words: IgA nephropathy, biomarkers, protein, nucleic acid, diagnosis, progression